Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs 10X Genomics Inc (TXG) Price & Performance

First Trust NASDAQ Clean Edge Green Energy Idx FdTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Clean Edge Green Energy Idx Fd vs 10X Genomics Inc — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.03, while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.

QCLNTXG
Sector
Sector/ThematicHealth
52-Week High
$68.47$47.20
52-Week Low
$34.31$11.34
Market Cap
$5.48B
Enterprise Value
$5.02B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN trades at $51.25, down 1.9% with a bearish technical signal showing 17 sell indicators versus 3 buy signals. The ETF faces headwinds from regulatory uncertainty around renewable energy permits and supply chain pressures, though long-term growth prospects remain supported by rising data center energy demand and global clean energy investments. Technical analysis indicates strong resistance at $52-$56 with support at $48-$51.

The clean energy sector faces near-term policy risks but benefits from structural tailwinds. Investment appeal depends on resolution of US permit delays and China trade tensions, with current technical weakness suggesting cautious entry points may emerge near support levels for long-term positioning in the energy transition theme.

10X Genomics Inc

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.

Returns comparison

Trailing returns across standard periods

About First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.

Read more on QCLN

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG